Skip to main content

Table 2 Patient Stratification by Gender

From: Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study

  # of Patients (%)
Characteristic Female Male P Value
Age (yrs) (n = 86)    0.26
   <60 37 (88.1%) 42 (95.5%)  
   >/=60 5 (11.9%) 2 (4.5%)  
Ethnicity (n = 87)    0.19
   Hispanic 23 (53.5%) 30 (68.2%)  
   Non-Hispanic 20 (46.5%) 14 (31.8%)  
Hemoglobin (g/dL) (n = 83)    0.019
   <12 34 (80.9%) 23 (56.1%)  
   >/=12 8 (19.1%) 18(43.9%)  
Leukocyte count (× 109/L) (n = 85)    0.46
   <50 13 (30.2%) 9 (21.4%)  
   >/=50 30 (69.8%) 33 (78.6%)  
Platelets (× 109/L) (n = 82)    0.041
   <450 20 (48.8%) 30 (73.2%)  
   >/=450 21 (51.2%) 11 (26.8%)  
Hasford Score (n = 64)    1
   </=780 low-risk 19 (52.8%) 16 (57.1%)  
   >780 and </=1480 intermediate 12 (33.3%) 9 (32.1%)  
   >1480 high-risk 5 (13.9%) 3 (10.7%)  
Sokal Score (n = 65)    0.39
   <0.8 good prognosis 12 (33.3%) 13 (44.8%)  
   0.8–1.2 moderate prognosis 16 (44.4%) 8 (27.6%)  
   >1.2 poor prognosis 8 (22.2%) 8 (27.6%)  
CHR at 3 months, all treatments (n = 47)    0.23
   Yes 13 (50%) 15 (71.4%)  
   No 13 (50%) 6 (28.6%)  
CHR at 3 months, imatinib only (n = 36)    0.13
   Yes 12 (63.2%) 15 (88.2%)  
   No 7 (38.4%) 2 (11.8%)  
  1. Selected demographic and clinical features of CML patients are presented, stratified by gender.